Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio, Inc. (Nasdaq: ACET) is a clinical-stage biotechnology company engaged in the discovery and development of novel allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer. Leveraging advanced immunotherapy techniques, Adicet Bio is pioneering the use of gamma delta T cells engineered with chimeric antigen receptors (CARs) and T cell receptors (TCRs) to create 'off-the-shelf' therapies aimed at providing durable and effective treatments for patients.
Core Products and Pipeline:
- ADI-001: A first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, currently in a Phase 1 clinical trial for relapsed or refractory aggressive B cell non-Hodgkin's lymphoma and autoimmune diseases such as lupus nephritis.
- ADI-270: An armored gamma delta CAR T cell product candidate targeting CD70, in preclinical development for renal cell carcinoma and other CD70+ solid and hematological malignancies.
Recent Achievements and Collaborations:
- FDA clearance of the Investigational New Drug (IND) application for ADI-001 in lupus nephritis and initiation of Phase 1 clinical trial expected in 2Q 2024.
- Strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop next-generation engineered immune-cell therapeutics.
- Successful Series A financing round, raising $51 million led by Orbimed Partners, Orbimed Israel, and Novartis Ventures.
- Inducement awards granted to new employees as material inducements for employment, signifying ongoing growth and talent acquisition within the company.
- Presentation of promising preclinical data on ADI-270 at major scientific annual meetings, indicating robust anti-tumor activity and potential clinical benefits.
Financial Overview: Adicet Bio maintains a strong cash position with $247.6 million in cash and cash equivalents as of March 31, 2024, providing sufficient funding to support operations into the second half of 2026. The company continues to strategically invest in research and development, as well as in expanding its organizational capabilities.
Adicet Bio is at the forefront of innovation in the biotechnology space, striving to bring transformative therapies to patients with unmet medical needs. For more information, please visit Adicet Bio's official website.
Rhea-AI Summary
Adicet Bio grants inducement awards to new hires
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.9%
Tags
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.44%
Tags
Rhea-AI Summary
Adicet Bio, Inc. (Nasdaq: ACET) Grants Inducement Awards to New Hires: Adicet Bio, a biotechnology company, announced the granting of inducement awards to four new hires in July 2023. The awards consist of non-qualified stock options to purchase 73,400 shares of Adicet’s common stock at an exercise price of $2.67 per share. These awards were granted outside of Adicet’s stockholder-approved equity incentive plans pursuant to the Inducement Plan.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.24%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.35%
Tags
Rhea-AI Summary
Adicet Bio announces positive safety and efficacy data from Phase 1 study of ADI-001 for the potential treatment of aggressive B-cell non-Hodgkin's lymphoma. The study demonstrated a 71% overall response rate and 63% complete response rate across all dose levels, with favorable safety profiles. The company plans to transition the ADI-001 program into a potentially pivotal Phase 2 study in post-CAR T large B-cell lymphoma patients in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-54.29%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
-
Rhea-AI Summary
Adicet Bio grants inducement awards to new hires, offering stock options to purchase 34,800 shares of common stock at $5.48 per share. Vesting occurs over time, with full vesting on the fourth anniversary of each employee's start date, subject to continued employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.2%
Tags
Rhea-AI Summary
Adicet Bio presents preclinical data on ADI-270, an armored allogeneic gamma delta CAR T cell therapy candidate targeting CD70+ cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.15%
Tags
FAQ
What is the current stock price of Adicet Bio (ACET)?
The current stock price of Adicet Bio (ACET) is $0.914 as of November 21, 2024.
What is the market cap of Adicet Bio (ACET)?
The market cap of Adicet Bio (ACET) is approximately 78.3M.
What is Adicet Bio, Inc.?
Adicet Bio, Inc. is a clinical-stage biotechnology company focused on developing allogeneic gamma delta T cell therapies for the treatment of autoimmune diseases and cancer.
What are the key products in Adicet Bio's pipeline?
The key products include ADI-001, a CAR T cell therapy targeting CD20 for autoimmune diseases and aggressive B cell non-Hodgkin's lymphoma, and ADI-270, an armored CAR T cell candidate targeting CD70 for renal cell carcinoma.
What recent achievements has Adicet Bio made?
Recent achievements include FDA clearance for ADI-001 in lupus nephritis, successful strategic collaborations, significant financing rounds, and promising preclinical data presentations.
How is Adicet Bio financially positioned?
Adicet Bio has a strong cash position with $247.6 million in cash and equivalents as of March 31, 2024, funding operations into the second half of 2026.
What strategic collaborations has Adicet Bio entered into?
Adicet Bio has a strategic collaboration with Regeneron Pharmaceuticals to develop engineered immune-cell therapeutics using its gamma delta T cell allogeneic platform technology.
What is the focus of Adicet Bio's research and development?
Adicet Bio's R&D focuses on creating 'off-the-shelf' gamma delta T cell therapies engineered with CARs and TCRs for cancer and autoimmune diseases.
What are ADI-001 and ADI-270?
ADI-001 is a gamma delta T cell therapy targeting CD20 for non-Hodgkin's lymphoma and autoimmune diseases, while ADI-270 targets CD70 for renal cell carcinoma and other CD70+ cancers.
What makes Adicet Bio's approach unique?
Adicet Bio utilizes gamma delta T cells with CAR and TCR engineering, providing off-the-shelf, allogeneic therapies that offer durable and effective treatments for patients.
What is the significance of the FDA's fast track designation for ADI-001?
The fast track designation for ADI-001 by the FDA facilitates the development and expedites the review process for this promising therapy targeting lupus nephritis.
Where can I find more information about Adicet Bio?
For more information, visit Adicet Bio's official website at https://www.adicetbio.com.
Adicet Bio, Inc.
Nasdaq:ACET
ACET Rankings
ACET Stock Data
78.28M
69.64M
1.59%
76.44%
4.16%
Biotechnology
Pharmaceutical Preparations
United States of America
BOSTON